5
and the majority appears to be self-limited. However, severe exacerbations, including fatalities, have
been reported.
Among entecavir-treated nucleoside naive patients, post-treatment exacerbations had a median time to
onset of 23-24 weeks, and most were reported in HBeAg negative patients (see section 4.8). Hepatic
function should be monitored at repeated intervals with both clinical and laboratory follow-up for at
least 6 months after discontinuation of hepatitis B therapy. If appropriate, resumption of hepatitis B
therapy may be warranted.
Patients with decompensated liver disease: a higher rate of serious hepatic adverse events (regardless
of causality) has been observed in patients with decompensated liver disease, in particular in those
with Child-Turcotte-Pugh (CTP) class C disease, compared with rates in patients with compensated
liver function. Also, patients with decompensated liver disease may be at higher risk for lactic acidosis
and for specific renal adverse events such as hepatorenal syndrome. Therefore, clinical and laboratory
parameters should be closely monitored in this patient population (see also sections 4.8 and 5.1).
Lactic acidosis and severe hepatomegaly with steatosis: occurrences of lactic acidosis (in the absence
of hypoxaemia), sometimes fatal, usually associated with severe hepatomegaly and hepatic steatosis,
have been reported with the use of nucleoside analogues. As entecavir is a nucleoside analogue, this
risk cannot be excluded. Treatment with nucleoside analogues should be discontinued when rapidly
elevating aminotransferase levels, progressive hepatomegaly or metabolic/lactic acidosis of unknown
aetiology occur. Benign digestive symptoms, such as nausea, vomiting and abdominal pain, might be
indicative of lactic acidosis development. Severe cases, sometimes with fatal outcome, were associated
with pancreatitis, liver failure/hepatic steatosis, renal failure and higher levels of serum lactate.
Caution should be exercised when prescribing nucleoside analogues to any patient (particularly obese
women) with hepatomegaly, hepatitis or other known risk factors for liver disease. These patients
should be followed closely.
To differentiate between elevations in aminotransferases due to response to treatment and increases
potentially related to lactic acidosis, physicians should ensure that changes in ALT are associated with
improvements in other laboratory markers of chronic hepatitis B.
Resistance and specific precaution for lamivudine-refractory patients: mutations in the HBV
polymerase that encode lamivudine-resistance substitutions may lead to the subsequent emergence of
secondary substitutions, including those associated with entecavir associated resistance (ETVr). In a
small percentage of lamivudine-refractory patients, ETVr substitutions at residues rtT184, rtS202 or
rtM250 were present at baseline. Patients with lamivudine-resistant HBV are at higher risk of
developing subsequent entecavir resistance than patients without lamivudine resistance. The
cumulative probability of emerging genotypic entecavir resistance after 1, 2, 3, 4 and 5 years treatment
in the lamivudine-refractory studies was 6%, 15%, 36%, 47% and 51%, respectively. Virological
response should be frequently monitored in the lamivudine-refractory population and appropriate
resistance testing should be performed. In patients with a suboptimal virological response after 24
weeks of treatment with entecavir, a modification of treatment should be considered (see sections 4.5
and 5.1). When starting therapy in patients with a documented history of lamivudine-resistant HBV,
combination use of entecavir plus a second antiviral agent (which does not share cross-resistance with
either lamivudine or entecavir) should be considered in preference to entecavir monotherapy.
Pre-existing lamivudine-resistant HBV is associated with an increased risk for subsequent entecavir
resistance regardless of the degree of liver disease; in patients with decompensated liver disease,
virologic breakthrough may be associated with serious clinical complications of the underlying liver
disease. Therefore, in patients with both decompensated liver disease and lamivudine-resistant HBV,
combination use of entecavir plus a second antiviral agent (which does not share cross-resistance with
either lamivudine or entecavir) should be considered in preference to entecavir monotherapy.
Paediatric population: A lower rate of virologic response (HBV DNA < 50 IU/ml) was observed in
paediatric patients with baseline HBV DNA ≥ 8.0 log
10
IU/ml (see section 5.1). Entecavir should be
used in these patients only if the potential benefit justifies the potential risk to the child (e.g.